Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study

Fig. 3

Kidney disease severity status (eGFR slope) shift from pre-switch to post-switch (efficacy population). Fast-progressing: eGFR slope <  − 5 mL/min/1.73 m2/year [4]. Progressing: eGFR slope ≥  − 5 to <  − 3 mL/min/1.73 m2/year. Stable: eGFR slope ≥  − 3 mL/min/1.73 m2/year. eGFR estimated glomerular filtration rate

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172